


HEALTHCARE

## **The Future of Monoclonal Antibody Therapeutics**

Innovation in antibody engineering, key growth strategies and forecasts to 2011

By Sarah Riley

 [Table of Contents](#)

## **Sarah Riley**

Sarah Riley is an analyst within the healthcare function of Business Insights. She has a PhD in physiology from King's College, London and is an expert in autoimmune diseases and cardiology. She has previously worked on commercial analyses of the generics market, the future of the diabetes market and pharmaceutical licensing strategies.

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Future of Monoclonal Antibody Therapeutics

<b>Executive Summary</b>	<b>12</b>	
<b>Introduction</b>	<b>12</b>	
<b>Antibody engineering and innovation in the market</b>	<b>13</b>	
<b>The current monoclonal antibody market</b>	<b>14</b>	
<b>The antibody pipeline and forecasts to 2011</b>	<b>15</b>	
<b>Competitive landscape and future growth strategies</b>	<b>16</b>	
<b>Chapter 1</b>	<b>Introduction</b>	<b>18</b>
<b>Summary</b>		<b>18</b>
<b>Introduction</b>		<b>19</b>
<b>History of monoclonal antibodies</b>		<b>20</b>
<b>Monoclonal antibody approval process</b>		<b>21</b>
Current approval process		21
Biogeneric regulations		22
<b>Key trends in the market</b>		<b>23</b>
Advancements in innovation		23
Diversification of therapy areas		24
Big Pharma entering the mAb market		25
<b>Chapter 2</b>	<b>Antibody engineering and innovation in the market</b>	<b>28</b>
<b>Summary</b>		<b>28</b>
<b>Introduction</b>		<b>29</b>
<b>The move from murine to fully human mAbs</b>		<b>30</b>
Whole IgG monoclonal antibodies		31
Murine		31
Chimeric		31
Humanized		32

Human	32
<b>Innovations in antibody structures</b>	<b>33</b>
Fab fragments	34
Single chain variable fragments	35
Extended release formulations	36
<b>Innovation in antibody conjugation</b>	<b>37</b>
Types of conjugation	37
Direct arming: antibody conjugation	37
Indirect arming: Bispecific monoclonal antibodies	37
Pre-targeting	38
Marketed conjugated monoclonal antibodies	38
Conjugation technology	39
Seattle Genetics antibody technology	39
ImmunoGen mAb technology	40
Peregrine mAb technology	41
<b>Enhancing monoclonal antibody potency</b>	<b>41</b>
<b>Drug discovery</b>	<b>42</b>
Cambridge Antibody Technology	44
Dyax	45
Morphosys	46
<b>Innovation in drug delivery</b>	<b>47</b>
Drug delivery devices	47
Inhaled monoclonal antibodies	48
Oral monoclonal antibodies	49

## **Chapter 3                      The current monoclonal antibody market                      52**

<b>Summary</b>	<b>52</b>
<b>Introduction</b>	<b>53</b>
<b>Strategic analysis</b>	<b>53</b>
Drivers	54
Pipeline drugs	54
Immature market	54
Big Pharma entering the mAb market	55
High level of innovation	55
Approval of new indications	56
Combination therapies	56
Resistors	56
Publicized side effects	56
Drugs suspended from market	57
Competition from small molecule drugs	57
Pricing and reimbursement schemes	57
<b>Analysis of launched drugs</b>	<b>58</b>
Oncology	60

	Rituxan	61
	Herceptin	63
	Avastin	65
	Erbitux	67
	Campath	69
	Zevalin	70
	MyloTarg	72
	Bexxar	74
AIID		76
	Remicade	76
	Humira	79
	Raptiva	81
	Simulect	83
	Zenapax	84
	OrthoClone OKT3	84
Hemostasis		86
	ReoPro	86
Anti-infectives		87
	Synagis	88
Respiratory		89
	Xolair	89
Marketed monoclonal antibody forecasts		90

## **Chapter 4                    The antibody pipeline and forecasts to 2011                    94**

<b>Summary</b>		<b>94</b>
<b>Introduction</b>		<b>95</b>
<b>Strategic analysis</b>		<b>95</b>
<b>Opportunities</b>		<b>97</b>
Clinical trials		97
	Erbitux and Avastin	98
	Simulect, Zenapax and Campath	98
	Campath	98
	Others	99
Innovation in antibody engineering		99
New indications		100
<b>Challenges</b>		<b>101</b>
Generic biologics		101
Adverse reactions in clinical trials, side effects and termination of development		102
High attrition rates		103
<b>Analysis of pipeline drugs</b>		<b>104</b>
AIID		109
	Cimzia	109
	MRA/Actemra	110

	Eculizumab	112
	AMG-162	113
Cardiovascular		115
	Pexelizumab	115
Infectious diseases		116
	Numax	116
Oncology		117
	ABX-EGF	117
	MDX-010+MDX-1379	119
	Humax	120
Ophthalmology		121
	Lucentis	121
<b>Late stage pipeline forecasts</b>		<b>123</b>
<b>The antibody market in 2011</b>		<b>124</b>

## **Chapter 5                      Competitive landscape and future growth strategies                      128**

<b>Summary</b>		<b>128</b>
<b>Introduction</b>		<b>129</b>
<b>Key players in the monoclonal antibody market</b>		<b>130</b>
<b>M&amp;A and licensing activity</b>		<b>130</b>
Big Pharma acquiring biotechs and antibody companies		133
	AstraZeneca and CAT	134
	Novartis and NeuTec	134
	Amgen and Abgenix	135
	Roche and GlycArt	135
	MedImmune and Collective Therapeutics	136
	Pfizer and Bioren	136
<b>Company profiles</b>		<b>137</b>
<b>Big Pharma</b>		<b>137</b>
Roche		137
	Company overview	137
	Strategic and growth analysis	137
	Marketed products	139
	Pipeline	140
Novartis		141
	Company overview	141
	Strategic and growth analysis	141
	Marketed products	142
	Pipeline	143
Pfizer		144
	Company overview	144
	Strategic and growth analysis	144
	Pipeline	146

<b>Large biotech</b>		<b>147</b>
Genentech		147
	Company overview	147
	Strategic and growth analysis	147
	Marketed products	148
	Pipeline	149
MedImmune		150
	Company Profile	150
	Strategic and growth analysis	150
	Marketed products	152
	Pipeline products	152
Biogen Idec		153
	Company overview	153
	Strategic analysis	153
	Marketed products	156
	Pipeline products	157
UCB-Celltech		157
	Company overview	157
	Strategic and growth analysis	158
	Marketed products	159
	Pipeline products	160
<b>Small biotech/antibody companies</b>		<b>161</b>
Medarex		161
	Company overview	161
	Strategic and growth analysis	161
	Marketed products	163
	Pipeline products	163
XOMA		165
	Company overview	165
	Strategic and growth analysis	165
	Marketed products	167
	Pipeline products	167
<b>Technology companies</b>		<b>169</b>
BioWa		169
	Company overview	169
	Strategic and growth analysis	169
	Pipeline products	171
Crucell		172
	Company overview	172
	Strategic and growth analysis	172
	Pipeline products	174

<b>Chapter 6</b>	<b>Appendix</b>	<b>178</b>
Sales data		178
Index		179

# List of Figures

Figure 1.1:	History of monoclonal antibodies	21
Figure 2.2:	Current marketed monoclonal antibodies, 2006	31
Figure 2.3:	Therapeutic mAbs entering clinical study, 1980-2004	33
Figure 2.4:	Whole antibody and fragment structures	34
Figure 3.5:	Drivers and resistors to growth in the monoclonal antibody market	54
Figure 3.6:	Market dynamics of current marketed drugs, 2004-5	58
Figure 3.7:	Marketed monoclonal antibodies by therapy area, 2006	60
Figure 4.8:	Opportunities and challenges in the mAb market	97
Figure 4.9:	Antibody structure analysis of forecasted monoclonal antibody sales (\$m), 2004-11	106
Figure 4.10:	Therapy area analysis in monoclonal antibody drug development, 2006	107
Figure 4.11:	Therapy area analysis of forecasted monoclonal antibody sales (\$m), 2004-11	108
Figure 5.12:	Key growth strategies in the monoclonal antibody market, 2005-6	133
Figure 5.13:	Roche's SWOT analysis in the mAb market	138
Figure 5.14:	Novartis' SWOT analysis in the mAb market	141
Figure 5.15:	Pfizer's SWOT analysis in the mAb market	145
Figure 5.16:	Genentech's SWOT analysis in the mAb market	148
Figure 5.17:	MedImmune's SWOT analysis in the mAb market	150
Figure 5.18:	Biogen Idec's SWOT analysis in the mAb market	154
Figure 5.19:	UCB Celltech's SWOT analysis in the mAb market	159
Figure 5.20:	Medarex's SWOT analysis in the mAb market	162
Figure 5.21:	XOMA's SWOT analysis in the mAb market	166
Figure 5.22:	BioWa's SWOT analysis in the mAb market	170
Figure 5.23:	Crucell's SWOT analysis in the mAb market	173

# List of Tables

Table 1.1:	Current marketed drugs, 2006	24
Table 1.2:	Key players in the monoclonal antibody market, 2006	25
Table 2.3:	Marketed therapeutic monoclonal antibodies, 1986-2006	30
Table 2.4:	Antibody fragment pipeline, 2006	36
Table 2.5:	Conjugated antibody engineering technology	39
Table 2.6:	Drug development technology	42
Table 2.7:	Monoclonal antibody drug discovery technology	43
Table 3.8:	Marketed therapeutic monoclonal antibodies, 2004-5	59
Table 3.9:	Marketed monoclonal antibody sales forecasts, 2005-11	91
Table 4.10:	Other post-marketing clinical trials, 2005-6	99
Table 4.11:	Late stage monoclonal antibody pipeline, 2006	105
Table 4.12:	Late stage monoclonal antibody pipeline sales forecast to 2011	124
Table 5.13:	Key players in the monoclonal antibody market, 2006	130
Table 5.14:	Monoclonal antibody collaborations, manufacturing, development and supply agreements, 2005-6	131
Table 5.15:	Key acquisitions in the monoclonal antibody market, 2005-6	134
Table 5.16:	Roche's marketed monoclonal antibodies, 2006	139
Table 5.17:	Roche's monoclonal antibody pipeline, 2006	140
Table 5.18:	Novartis' marketed monoclonal antibodies, 2006	143
Table 5.19:	Novartis' monoclonal antibody pipeline, 2006	143
Table 5.20:	Pfizer's monoclonal antibody pipeline, 2006	146
Table 5.21:	Genentech's marketed monoclonal antibodies, 2006	149
Table 5.22:	Genentech's monoclonal antibody pipeline, 2006	149
Table 5.23:	MedImmune's marketed monoclonal antibodies, 2006	152
Table 5.24:	MedImmune's monoclonal antibody pipeline, 2006	152
Table 5.25:	Biogen Idec's marketed monoclonal antibodies, 2006	156
Table 5.26:	Biogen Idec's monoclonal antibody pipeline, 2006	157
Table 5.27:	UCB-Celltech monoclonal antibody pipeline, 2006	160
Table 5.28:	Medarex's monoclonal antibody pipeline, 2006	163
Table 5.29:	XOMA's monoclonal antibody pipeline, 2006	167
Table 5.30:	BioWa's monoclonal antibody pipeline, 2006	171
Table 5.31:	Crucell's monoclonal antibody pipeline, 2006	174